This Orphan Drugmaker Deserves a Spot on Your Radar

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 20 July, 2015 by The TZ Newswire Staff

This Orphan Drugmaker Deserves a Spot on Your Radar

Orphan drug maker BioMarin has been a terrific stock for long-term investors, but is its pipeline strong enough to continue to propel the stock higher?

See also
- Next Article JPMorgan falls $12.5 billion short of meeting Fed’s capital requirements
- Previous Article The Wall Street Journal: Venture capitalist to spend $100 million on search for aliens
Editorial Calender

July 2015

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Jun Aug »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 20 July, 2015 by The TZ Newswire Staff

This Orphan Drugmaker Deserves a Spot on Your Radar

See also

Editorial Calender

Recent Tags